N

NeuroBo Pharmaceuticals
D

NRBO

2.35000
USD
-0.10
(-4.08%)
Market Closed
Volume
349
EPS
-5
Div Yield
-
P/E
-1
Market Cap
20,247,624
OverviewSignalsIdeasNews
Related Instruments
    A
    ADMP
    0
    (0%)
    0.000000 USD
    A
    ARDX
    0.25000
    (5.30%)
    4.96500 USD
    B
    BPMC
    -6.990
    (-7.31%)
    88.690 USD
    B
    BTAI
    0.05300
    (10.50%)
    0.55800 USD
    E
    EVLO
    0
    (0%)
    0.000000 USD
    M
    MDGL
    -13.55
    (-4.48%)
    288.99 USD
    T
    TNXP
    -0.00910
    (-6.53%)
    0.13030 USD
    V
    VKTX
    -3.960
    (-7.39%)
    49.620 USD
    More
News

Title: NeuroBo Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.